메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

'김갑성' 기자의 전체기사

US BioTek Laboratories Completes Merger With NutriPATH Patho…

SEATTLE and MELBOURNE, Australia, March 3, 2026 -- US BioTek Laboratories, a leading functional laboratory specializing in advanced immunological and integrative diagnostics, today announced the completion of its merger with NutriPATH Pathology, a respected functional pathology laboratory serving integrative and functional medicine practitioners. The merger marks a significant milestone for the global functional laboratory industry. It brings together the two organizations' specialized expertise and a shared commitment to clinical relevance, scientific rigor, and practitioner s
- 김갑성 기자
- 2026-03-03 02:15
Skyhawk Announces Australia's Therapeutic Goods Admini…

[ 메디채널 김갑성 기자 ] Australia's Therapeutic Goods Administration (TGA), responsible for approval of the safety, quality, and efficacy of therapeutic goods, has determined that Skyhawk's SKY-0515 orally-administered small molecule therapy for the treatment of Huntington's disease meets TGA eligibility criteria for registration via the provisional approval pathway. Skyhawk delivered its application for provisional approval to the TGA today. More than 115 patients are now on trial with SKY-0515. BOSTON, March 3, 2026 -- Skyhawk Therapeutics, Inc., a clinical-stage biotechnolog
- 김갑성 기자
- 2026-03-03 01:20
Innovaccer Receives Frost & Sullivan's 2026 United States New…

[ 메디채널 김갑성 기자 ] The recognition highlights Innovaccer's innovation leadership in transforming patient access through omnichannel, AI-powered engagement and workflow unification. SAN ANTONIO, March 3, 2026 -- Frost & Sullivan is pleased to announce that Innovaccer has received the 2026 United States New Product Innovation Recognition in the United States Patient Access Solutions Industry for its outstanding achievements in innovation, strategy execution, and customer impact. This recognition highlights Innovaccer's consistent leadership in modernizing patient access through AI-dri
- 김갑성 기자
- 2026-03-03 00:57
The Sigourney Award-2026 Now Accepting Applications for Ps…

International Prize Honors Trailblazing Work Advancing Psychoanalytic Thought and Principles — Cash Award and Global Recognition SAN FRANCISCO, March 2, 2026 -- The Sigourney Award Trust welcomes applications for The Sigourney Award-2026 from individuals, teams, and organizations worldwide whose work has advanced psychoanalytic thinking and principles. Applications are open through July 31, 2026, for work completed between 2016 and 2025. The Trust was established in 1989 by psychotherapist and community activist Mary Sigourney with a clear vision: to encourage bold, orig
- 김갑성 기자
- 2026-03-02 22:49
XellSmart Receives Fourth Consecutive US FDA & China NMPA IND…

SUZHOU, China, March 2, 2026 -- In February 2026, XellSmart Pharmaceutical Co., Ltd. (XellSmart) announced that it had secured its fourth US FDA and China NMPA clearance for Phase I/II registrational clinical trial entry with its independently developed, off-the-shelf, allogeneic, universal, iPSC-derived, subtype-specific neuron progenitor cell therapy targeting Multiple System Atrophy- Parkinsonian Type (MSA-P). This joins the previous three consecutive FDA-NMPA registrational trial clearances for its universal iPSC-derived cell therapies targeting Parkinson's Disease (PD), Spinal Cord Injur
- 김갑성 기자
- 2026-03-02 22:10
Superior Efficacy and Long-acting: LongBio Announces…

PHILADELPHIA, March 2, 2026 -- LongBio Pharma (Suzhou) Co., Ltd. ("LongBio"), a clinical-stage biotech company focused on discovery and development of biologics targeting allergic and autoimmune diseases, proudly announced positive topline results from a Phase II clinical trial of its next-generation anti-IgE antibody, LP-003, with a head-to-head comparison with Xolair® (Omalizumab). The data was presented as a late-breaking poster at the 2026 AAAAI Annual Meeting. The results demonstrated that LP-003 achieved comprehensive clinical advantages over omalizumab, with statistically
- 김갑성 기자
- 2026-03-02 22:00
ReviR Therapeutics Announces First Participant Dosed in Ph…

[ 메디채널 김갑성 기자 ] Milestone marks the first clinical program for Charcot-Marie-Tooth disease and Vanishing White Matter disease. SAN FRANCISCO and SHANGHAI, March 2, 2026 -- ReviR Therapeutics, a clinical-stage biotechnology company pioneering AI-driven RNA-modulating small molecules to treat rare and genetic diseases, today announced a pivotal clinical and dual regulatory milestone: the first participant has been dosed in the First-in-Human (FIH) Phase 1 clinical trial of its lead candidate, RTX-117. This clinical progress follows the recent clearance by the Center for Drug Evaluation
- 김갑성 기자
- 2026-03-02 22:00
Halia Therapeutics Announces Presentation at the BIO Inve…

LEHI, Utah, March 2, 2026 -- Halia Therapeutics, a clinical-stage biopharmaceutical company advancing therapies grounded in human biology, today announced that it will deliver a company presentation at the BIO Investment & Growth Summit. David Bearss, Ph.D., Chief Executive Officer of Halia Therapeutics, will present an overview of the company's strategy, platform, and clinical programs. Presentation Details Event: BIO Investment & Growth SummitDate/Time: Monday, March 2, 2026 at 2:30 PMLocation: Ballroom I, Salon C About NEK7 NEK7 is a cr
- 김갑성 기자
- 2026-03-02 21:35
The largest pharma show in Asia makes its return to Shangh…

SHANGHAI, March 2, 2026 -- CPHI & PMEC China 2026 is set to take place from 16 to 18 June 2026 at the Shanghai New International Expo Centre (SNIEC), building on its extremely successful run over the last few years. As the world's premier destination for pharmaceutical ingredients and manufacturing solutions, this year's edition is set to bring together over 110,000 attendees, and more than 3,600 local and international exhibitors. This comfortably makes CPHI & PMEC China Asia's largest pharma event, offering unparalleled opportunities to source, supply and innovate wit
- 김갑성 기자
- 2026-03-02 20:09
ECR 2026: Esaote Group Introduces Breakthroughs in Ultraso…

The new MyLab™E85 GTS and MyLab™C30 GTS Edition ultrasound systems will be presented on Thursday, 5th March at 11.30 a.m. at the Esaote Booth GENOA, Italy, March 2, 2026 -- Esaote Group, a leading Italian innovator in medical imaging – ultrasound, dedicated magnetic resonance and medical IT – attends European Congress of Radiology 2026 in Vienna (March 4-8, Booth 505 Expo Hall X5) with a renewed commitment to supporting radiologists in delivering accurate diagnoses and improved patient outcomes. At ECR 2026, Esaote places particular emphasis on ultrasound innovat
- 김갑성 기자
- 2026-03-02 19:30

이전

1 2 3 4 5 6 7 8 9 10

많이 본 기사

최근기사

2026-03-03_TUE

2026-03-02_MON

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2026년 03월 03일 06시 30분